Anthrax prophylaxis: recent advances and future directions
Anthrax is a serious, potentially fatal disease that can present in four distinct clinical patterns depending on the route of infection (cutaneous, gastrointestinal, pneumonic, or injectional); effective strategies for prophylaxis and therapy are therefore required. This review addresses the complex...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Frontiers Media S.A.
2015
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4585224/ |
| id |
pubmed-4585224 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-45852242015-10-05 Anthrax prophylaxis: recent advances and future directions Williamson, E. Diane Dyson, Edward Hugh Public Health Anthrax is a serious, potentially fatal disease that can present in four distinct clinical patterns depending on the route of infection (cutaneous, gastrointestinal, pneumonic, or injectional); effective strategies for prophylaxis and therapy are therefore required. This review addresses the complex mechanisms of pathogenesis employed by the bacterium and describes how, as understanding of these has developed over many years, so too have current strategies for vaccination and therapy. It covers the clinical and veterinary use of live attenuated strains of anthrax and the subsequent identification of protein sub-units for incorporation into vaccines, as well as combinations of protein sub-units with spore or other components. It also addresses the application of these vaccines for conventional prophylactic use, as well as post-exposure use in conjunction with antibiotics. It describes the licensed acellular vaccines AVA and AVP and discusses the prospects for a next generation of recombinant sub-unit vaccines for anthrax, balancing the regulatory requirement and current drive for highly defined vaccines, against the risk of losing the “danger” signals required to induce protective immunity in the vaccinee. It considers novel approaches to reduce time to immunity by means of combining, for example, dendritic cell vaccination with conventional approaches and considers current opportunities for the immunotherapy of anthrax. Frontiers Media S.A. 2015-09-24 /pmc/articles/PMC4585224/ /pubmed/26441934 http://dx.doi.org/10.3389/fmicb.2015.01009 Text en Copyright © 2015 Williamson and Dyson. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Williamson, E. Diane Dyson, Edward Hugh |
| spellingShingle |
Williamson, E. Diane Dyson, Edward Hugh Anthrax prophylaxis: recent advances and future directions |
| author_facet |
Williamson, E. Diane Dyson, Edward Hugh |
| author_sort |
Williamson, E. Diane |
| title |
Anthrax prophylaxis: recent advances and future directions |
| title_short |
Anthrax prophylaxis: recent advances and future directions |
| title_full |
Anthrax prophylaxis: recent advances and future directions |
| title_fullStr |
Anthrax prophylaxis: recent advances and future directions |
| title_full_unstemmed |
Anthrax prophylaxis: recent advances and future directions |
| title_sort |
anthrax prophylaxis: recent advances and future directions |
| description |
Anthrax is a serious, potentially fatal disease that can present in four distinct clinical patterns depending on the route of infection (cutaneous, gastrointestinal, pneumonic, or injectional); effective strategies for prophylaxis and therapy are therefore required. This review addresses the complex mechanisms of pathogenesis employed by the bacterium and describes how, as understanding of these has developed over many years, so too have current strategies for vaccination and therapy. It covers the clinical and veterinary use of live attenuated strains of anthrax and the subsequent identification of protein sub-units for incorporation into vaccines, as well as combinations of protein sub-units with spore or other components. It also addresses the application of these vaccines for conventional prophylactic use, as well as post-exposure use in conjunction with antibiotics. It describes the licensed acellular vaccines AVA and AVP and discusses the prospects for a next generation of recombinant sub-unit vaccines for anthrax, balancing the regulatory requirement and current drive for highly defined vaccines, against the risk of losing the “danger” signals required to induce protective immunity in the vaccinee. It considers novel approaches to reduce time to immunity by means of combining, for example, dendritic cell vaccination with conventional approaches and considers current opportunities for the immunotherapy of anthrax. |
| publisher |
Frontiers Media S.A. |
| publishDate |
2015 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4585224/ |
| _version_ |
1613480718115012608 |